Akorn in pre-mix deal with Bioluz

US firm Akorn has signed a memorandum of understanding with Bioluz SA, a privately-held French company, for five pre-mix products. The estimated market size of these agents, based on recent IMS data, is about $175.0 million. Pre-mix medications are ready to use intravenous drug products that eliminate compounding steps in the pharmacy or at the point of care.

Under the terms of the accord, Akorn will be responsible for the development, regulatory filings, marketing and distribution of the pre-mix product line. Bioluz will exclusively manufacture the products at its intravenous solutions manufacturing facility and Akorn will own the Abbreviated New Drug Applications. Financial terms were not disclosed, but both parties expect to execute the definitive development and supply agreement within 60 days.